Immunosuppressive therapy in pediatric inflammatory bowel disease: results of a survey of the North American Society for Pediatric Gastroenterology and Nutrition. Subcommittee on Immunosuppressive Use of the Pediatric IBD Collaborative Research Forum.

摘要: We report the results of a survey membership North American Society for Pediatric Gastroenterology and Nutrition designed to determine pediatric gastroenterologists' attitudes toward use immunosuppressive therapy inflammatory bowel disease (IBD), assess how these medications are actually being used in treatment children with IBD. One hundred five physicians (27% surveys) responded. Eighty-eight (84%) had prescribed 6-mercaptopurine and/or azathioprine IBD, 66 believed that they were effective. Only 12 cyclosporine four methotrexate. All who immunosuppressives IBD them patients Crohn's disease, but only 50% ulcerative colitis. The predominant indications included intractable symptoms despite traditional medical (92%) corticosteroid-sparing effects (86%). Potential toxicities greatest concern marrow immune suppression malignancy. vast majority responders not certain what recommend respect agents prior during pregnancy. A clinical database was compiled from 165 retrospective case reports submitted by 45 (33 facilities). At start therapy, 15.3 +/- 4.0 yr age, 52% Tanner IV-V. Eighty-one percent 8% colitis, 11% indeterminant twenty-two treated 6-mercaptopurine, 43 azathioprine. Five also received concomitantly. Overall, 68% an improved. Complications requiring discontinuation occurred 6% patients. It appears commonly treat paucity data regarding their safety efficacy this age group. Controlled, prospective trials warranted better define role